Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors

Background: Risk-adjusted cancer screening and prevention is a promising and continuously emerging option for improving cancer prevention. It is driven by increasing knowledge of risk factors and the ability to determine them for individual risk prediction. However, there is a knowledge gap between evidence of increased risk and evidence of the effectiveness and efficiency of clinical preventive interventions based on increased risk. This gap is, in particular, aggravated by the extensive availability of genetic risk factor diagnostics, since the question of appropriate preventive measures immediately arises when an increased risk is identified. However, collecting proof of effective preventive measures, ideally by prospective randomized preventive studies, typically requires very long periods of time, while the knowledge about an increased risk immediately creates a high demand for action. Summary: Therefore, we propose a risk-adjusted prevention concept that is based on the best current evidence making needed and appropriate preventive measures available, and which is constantly evaluated through outcome evaluation, and continuously improved based on these results. We further discuss the structural and procedural requirements as well as legal and socioeconomical aspects relevant for the implementation of this concept.

[1]  A. Antoniou,et al.  Performance of breast cancer polygenic risk scores in 760 female CHEK2 germline mutation carriers. , 2020, Journal of the National Cancer Institute.

[2]  A. Uitterlinden,et al.  Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort , 2020, Genetics in Medicine.

[3]  S. Boccia,et al.  A review of the legislation of direct-to-consumer genetic testing in EU member states. , 2020, European journal of medical genetics.

[4]  R. Ádány,et al.  How to Integrate Personalized Medicine into Prevention? Recommendations from the Personalized Prevention of Chronic Diseases (PRECeDI) Consortium , 2019, Public Health Genomics.

[5]  P. V. van Diest,et al.  Supplemental MRI Screening for Women with Extremely Dense Breast Tissue. , 2019, The New England journal of medicine.

[6]  Gretchen L. Gierach,et al.  Toward Risk-Stratified Breast Cancer Screening: Considerations for Changes in Screening Guidelines. , 2019, JAMA oncology.

[7]  H. Brenner,et al.  Risk-Adapted Starting Age of Screening for Relatives of Patients With Breast Cancer. , 2019, JAMA oncology.

[8]  M. Hellmich,et al.  Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohort , 2019, The breast journal.

[9]  Gord Glendon,et al.  10-year performance of four models of breast cancer risk: a validation study. , 2019, The Lancet. Oncology.

[10]  M. García-Closas,et al.  BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors , 2019, Genetics in Medicine.

[11]  Kristen S Purrington,et al.  Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes , 2018, American Journal of Human Genetics.

[12]  S. Lönnberg,et al.  The legal framework for European cervical cancer screening programmes , 2018, European journal of public health.

[13]  A. Meindl,et al.  Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history , 2018, BMC Cancer.

[14]  A. Reuss,et al.  Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1) , 2017, PloS one.

[15]  W. Chung,et al.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.

[16]  W. Chung,et al.  Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers , 2017, Journal of the National Cancer Institute.

[17]  Muin J Khoury,et al.  A knowledge base for tracking the impact of genomics on population health , 2016, Genetics in Medicine.

[18]  Muin J Khoury,et al.  Convergence of Implementation Science, Precision Medicine, and the Learning Health Care System: A New Model for Biomedical Research. , 2016, JAMA.

[19]  I. Slade,et al.  Preparing clinicians for genomic medicine , 2016, Postgraduate Medical Journal.

[20]  Zicheng Xu,et al.  Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review , 2016, Clinical Cancer Research.

[21]  T. Pang,et al.  Evidence for Health III: Making evidence-informed decisions that integrate values and context , 2016, Health Research Policy and Systems.

[22]  Tanja Fehm,et al.  Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer , 2016, Journal of Medical Genetics.

[23]  G. Parmigiani,et al.  Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. , 2016, JAMA.

[24]  M. Khoury,et al.  Targeted Cancer Screening in Average-Risk Individuals. , 2015, American journal of preventive medicine.

[25]  H. D. de Koning,et al.  Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC) , 2015, International journal of cancer.

[26]  Nazneen Rahman,et al.  Gene-panel sequencing and the prediction of breast-cancer risk. , 2015, The New England journal of medicine.

[27]  P. Pharoah,et al.  Do Health Professionals Need Additional Competencies for Stratified Cancer Prevention Based on Genetic Risk Profiling? , 2015, Journal of personalized medicine.

[28]  C. Marchetti,et al.  Bilateral Risk-Reduction Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Meta-analysis , 2015, Annals of Surgical Oncology.

[29]  M. Khoury,et al.  Opportunities for Translational Epidemiology: The Important Role of Observational Studies to Advance Precision Oncology , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[30]  M. Khoury,et al.  What is translational genomics? An expanded research agenda for improving individual and population health , 2014, Applied & translational genomics.

[31]  R. Busse,et al.  The new regulation to investigate potentially beneficial diagnostic and therapeutic methods in Germany: up to international standard? , 2014, Health policy.

[32]  M. Khoury,et al.  Utility before business , 2014, Genetics in Medicine.

[33]  R. Tollenaar,et al.  Improved overall survival after contralateral risk‐reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis , 2014, International journal of cancer.

[34]  H. Burton,et al.  Personalised medicine in the UK: challenges of implementation and impact on healthcare system , 2014, Genome Medicine.

[35]  Wylie Burke,et al.  Genetic Tests: Clinical Validity and Clinical Utility , 2014, Current protocols in human genetics.

[36]  M. Leach,et al.  MRI breast screening in high-risk women: cancer detection and survival analysis , 2014, Breast Cancer Research and Treatment.

[37]  Paul K. J. Han,et al.  Presenting quantitative information about decision outcomes: a risk communication primer for patient decision aid developers , 2013, BMC Medical Informatics and Decision Making.

[38]  E. Birney,et al.  Policy challenges of clinical genome sequencing , 2013, BMJ.

[39]  P. Pharoah,et al.  Public health genomics and personalized prevention: lessons from the COGS project , 2013, Journal of internal medicine.

[40]  P. Pharoah,et al.  Implementing risk-stratified screening for common cancers: a review of potential ethical, legal and social issues , 2013, Journal of public health.

[41]  P. Pharoah,et al.  Public health implications from COGS and potential for risk stratification and screening , 2013, Nature Genetics.

[42]  G. Elwyn,et al.  Personalised risk communication for informed decision making about taking screening tests. , 2013, The Cochrane database of systematic reviews.

[43]  P. Hall,et al.  Incorporating genomics into breast and prostate cancer screening: assessing the implications , 2013, Genetics in Medicine.

[44]  A. Cecile J.W. Janssens,et al.  How can polygenic inheritance be used in population screening for common diseases? , 2013, Genetics in Medicine.

[45]  R. Eeles,et al.  Stratified Cancer Screening: The Practicalities of Implementation , 2013, Public Health Genomics.

[46]  A. Brand,et al.  European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome-based Information and Technologies: the 2012 Declaration of Rome , 2012, Drug metabolism and drug interactions.

[47]  W. Gaissmaier,et al.  Numbers can be worth a thousand pictures: individual differences in understanding graphical and numerical representations of health-related information. , 2012, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[48]  Julie O. Culver,et al.  Essential Elements of Genetic Cancer Risk Assessment, Counseling, and Testing: Updated Recommendations of the National Society of Genetic Counselors , 2012, Journal of Genetic Counseling.

[49]  S. Athar Principles of Biomedical Ethics , 2011, The Journal of IMA.

[50]  Edward T. Cokely,et al.  Effective communication of risks to young adults: using message framing and visual aids to increase condom use and STD screening. , 2011, Journal of experimental psychology. Applied.

[51]  M. Galesic,et al.  Corrigendum to: "Who profits from visual aids: Overcoming challenges in people's understanding of risks" [Social Science & Medicine, 70 (2010), 1019-1025. , 2010, Social science & medicine.

[52]  Gerd Gigerenzer,et al.  Do Icon Arrays Help Reduce Denominator Neglect? , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.

[53]  Heather Skirton,et al.  Genetic education and the challenge of genomic medicine: development of core competences to support preparation of health professionals in Europe , 2010, European Journal of Human Genetics.

[54]  A. Andermann,et al.  Genetic Screening: A Conceptual Framework for Programmes and Policy-Making , 2010, Journal of health services research & policy.

[55]  M. Galesic,et al.  Who profits from visual aids: overcoming challenges in people's understanding of risks [corrected]. , 2010, Social science & medicine.

[56]  M. Galesic,et al.  Statistical Numeracy for Health A Cross-cultural Comparison With Probabilistic National Samples , 2010 .

[57]  A. Andermann,et al.  Guiding Policy Decisions for Genetic Screening: Developing a Systematic and Transparent Approach , 2009, Public Health Genomics.

[58]  Steven Woloshin,et al.  Using a Drug Facts Box to Communicate Drug Benefits and Harms Two Randomized Trials , 2009, Annals of Internal Medicine.

[59]  A. Andermann,et al.  Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. , 2008, Bulletin of the World Health Organization.

[60]  J Dundon,et al.  Interventions to improve risk communication in clinical genetics: systematic review. , 2008, Patient education and counseling.

[61]  Lisa M. Schwartz,et al.  PSYCHOLOGICAL SCIENCE IN THE PUBLIC INTEREST Helping Doctors and Patients Make Sense of Health Statistics , 2022 .

[62]  S. Narod Modifiers of risk of hereditary breast cancer , 2006, Oncogene.

[63]  P. Ubel,et al.  Reducing the Influence of Anecdotal Reasoning on People’s Health Care Decisions: Is a Picture Worth a Thousand Statistics? , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.

[64]  J. Kaprio,et al.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.

[65]  Nancy L. Kocovski,et al.  Perception of Quantitative Information for Treatment Decisions , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.

[66]  G. Gigerenzer,et al.  The Barrier to Informed Choice in Cancer Screening: Statistical Illiteracy in Physicians and Patients. , 2018, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[67]  P. Pharoah,et al.  Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model , 2018 .

[68]  REGULATION (EU) 2019/518 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL , 2015 .

[69]  Additional protocol to the convention on human rights and biomedicine, concerning genetic testing for health purposes. , 2008, Revista de derecho y genoma humano = Law and the human genome review.

[70]  Ja Wilson,et al.  Principles and practice of screening for disease , 1968 .